Commentary Two hard questions

At BioCentury we have been nattering on for two years about the necessity for companies to demonstrate a Clear Route to ROI for investors. Last week, at the fifth Clear Route investment conference in New York, members of the Street community provided some concrete ways to do so.

Several of the meeting's luncheon panelists, among them Marc Ostro of UBS Securites and Stuart Weisbrod of Oracle Partners, raised cautions about the role of technology in the